Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer

Rhea-AI Summary

Turning Point Therapeutics (NASDAQ: TPTX) announced that an abstract for its TRIDENT-1 clinical study of repotrectinib will be presented at the IASLC 2020 World Conference on Lung Cancer on January 31, 2021. Repotrectinib is a next-generation kinase inhibitor targeting oncogenic drivers in non-small cell lung cancer. The company is also advancing other drug candidates such as TPX-0022, TPX-0046, and TPX-0131 in various stages of clinical trials. Upcoming details on the presentation will be released on December 16, 2020, and January 12, 2021.

Positive

• Abstract for TRIDENT-1 clinical study selected for presentation at IASLC 2020.
• Repotrectinib shows antitumor activity and durable responses in trials.
• Pipeline includes potential therapies targeting MET, RET, and ALK.

Negative

• None.

SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that an abstract for the TRIDENT-1 clinical study of its lead drug candidate repotrectinib has been selected for a mini-oral presentation on Jan. 31, 2021 at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer.

Additional details are anticipated to be released by IASLC, including presentation titles on Dec. 16 and abstracts on Jan. 12, 2021. For more information, visit https://wclc2020.iaslc.org/.

About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET and SRC, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor in IND-enabling studies. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, risks and uncertainties related to the impact of the COVID-19 pandemic to Turning Point’s business and the other risks described in Turning Point Therapeutics’ filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact:
Jim Mazzola
jim.mazzola@tptherapeutics.com
858-342-8272

FAQ

What is the TRIDENT-1 clinical study for TPTX?

The TRIDENT-1 study assesses the efficacy of repotrectinib, a drug targeting specific genetic drivers in cancer, particularly in non-small cell lung cancer.

When will the TRIDENT-1 study results be presented?

The study's abstract will be presented at the IASLC 2020 World Conference on Lung Cancer on January 31, 2021.

What is repotrectinib's role in oncology?

Repotrectinib is a next-generation kinase inhibitor designed to target ROS1 and TRK oncogenic drivers in cancer.

What are Turning Point Therapeutics' future plans?

The company is focused on advancing its pipeline of investigational drugs targeting various genetic alterations in cancer.

What should investors know about TPTX's clinical trials?

Investors should monitor the outcomes of the ongoing Phase 1/2 trials for repotrectinib and other candidates in the pipeline, as these results can significantly affect stock performance.